This study analyses the international debate on various aspects access to health products, particularly medicines and vaccines, for Covid-19: innovation strategies such as drug repurposing, high-level public debate about vaccines as global public goods, intellectual property rights and TRIPS flexibilities, technology transfer agreements, and trade issues. The pandemic has concentrated intense technological efforts, which, in the future, may stimulate renewed public policies on science, innovation and production, state capabilities, public-private partnerships, and the strategic allocation of investments contributing to technological catching-up processes